News

Marked Racial Disparity in Recognition, Treatment of Depression in ACS Patients


 

NEW ORLEANS — Underrecognition and undertreatment of clinically significant depression among patients with acute coronary syndrome is common—and strikingly more so among black patients, Alpesh A. Amin, M.D., reported at the annual scientific sessions of the American Heart Association.

Among 1,181 patients hospitalized with acute coronary syndrome (ACS) at two major Kansas City-area medical centers, the prevalence of moderate to severe depressive symptoms, as assessed by trained evaluators using the Primary Care Evaluation of Mental Disorders Brief Patient Health Questionnaire, was 14.9% among the 80.3% of ACS patients who were white—and fully twice as great in the 16.4% of patients who were black.

Yet these significant depressive symptoms were three times as likely to go unrecognized by clinicians in black than in white patients, said Dr. Amin, a research fellow at the Saint Luke's Hospital Center for Innovation and Research and the University of Missouri, Kansas City.

Moreover, the racial disparity in treatment of depression was even more pronounced than the disparity in recognition. Only 3.6% of black patients with moderate to severe depressive symptoms were discharged on antidepressant medication, compared with 28.5% of depressed white patients.

Depressive symptoms were recognized by clinicians in just 10.3% of black patients with moderate to severe depressive symptom scores, compared with 31.2% of affected white patients.

Recognizing depression should be an important goal for any physician who provides care for patients with ACS, Dr. Amin stressed. Depressed ACS patients have been shown to have a greater risk of future cardiac events and death than nondepressed ones.

In addition, the psychologic, social, and functional impairment inflicted by depression make depressive symptoms in patients with ACS worthy of treatment, regardless of whether antidepressant therapy improves cardiovascular outcomes—an issue currently under study.

Recommended Reading

Pioglitazone Beat Rosiglitazone In Lipid Level Improvement
MDedge Internal Medicine
Simvastatin, Pravastatin Lower Blood Pressure
MDedge Internal Medicine
High Folate Linked to Lower Risk Of Hypertension in Young Women
MDedge Internal Medicine
Body Mass Index Affects CV Event Rate in Hypertensives
MDedge Internal Medicine
Nomogram Calculates Women's Exercise Capacity
MDedge Internal Medicine
Family History of Heart Disease Boosts Coronary Risk in Sisters
MDedge Internal Medicine
Heart Disease Prevention Efforts Should Target Women in Midlife
MDedge Internal Medicine
Drugs, Methods Poised To Change Imaging
MDedge Internal Medicine
Coronary Calcium Screening Backed for High-Risk Patients
MDedge Internal Medicine
Normal Stress Echo Good for 18 Months in Patients With Prior MI
MDedge Internal Medicine